The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation
Open accessAbstract
OBJECTIVES: Glutamate mediated excitotoxicity of the hyperactive subthalamic nucleus (STN) has been reported to contribute to nigral degeneration in Parkinson's disease (PD). Deep brain stimulation of the STN (STN DBS), in its role as a highly effective treatment of severe PD motor complications, has been thought to inhibit STN hyperactivity and therefore decrease progression of PD. METHODS: In a prospective two centre study, disease progression was determined by means of serial (18)F-fluorodopa (F-dopa) positron emission tomography (PET) in 30 patients with successful STN DBS over the first 16 (SD 6) months after surgery. RESULTS: Depending on the method of PET data analysis used in the two centres, annual progression rates relative to baseline were 9.5-12.4% in the caudate and 10.7-12.9% in the putamen. CONCLUSIONS: This functional imaging study is the first to demonstrate a continuous decline of dopaminergic function in patients with advanced PD under clinically effective bilateral STN stimulation. The rates of progression in patients with STN DBS were within the range of previously reported data from longitudinal imaging studies in PD. Therefore this study could not confirm the neuroprotective properties of DBS in the STN target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Cited by
Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease
Benabid, A. L., Chabardes, S., Mitrofanis, J., & Pollak, P. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70291-6 · Cited by 1,285
Mechanisms of deep brain stimulation
Herrington, T. M., Cheng, J. J., & Eskandar, E. N. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00281.2015 · Cited by 551
“2011), and dopamine terminal loss continues to accrue at a rate similar to non-DBS-treated PD patients as assessed by (18)F-fluorodopa (F-dopa)-PET (Hilker et al. 2005).”
BackgroundResultInfluentialParsons, T. D., Rogers, S. A., Braaten, A. J., Woods, S. P., & Tröster, A. I. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70475-6 · Cited by 500
Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants
Fasano, A., Romito, L. M., Daniele, A., Piano, C., Zinno, M., Bentivoglio, A. R., & Albanese, A. (2010) · Brain · doi:10.1093/brain/awq221 · Cited by 429
Deep Brain Stimulation for Neurologic and Neuropsychiatric Disorders
Wichmann, T., & DeLong, M. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.022 · Cited by 331
Review: Deep brain stimulation in Parkinson’s disease
Groiss, S. J., Wojtecki, L., Südmeyer, M., & Schnitzler, A. (2009) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285609339382 · Cited by 280
Pathomechanisms and compensatory efforts related to Parkinsonian speech
Arnold, C., Gehrig, J., Gispert, S., Seifried, C., & Kell, C. A. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.10.016 · Cited by 98
“Speech and language therapy regimes that focus on voice symptoms by training patients in speaking more loudly and with more increased vocal effort are a particularly effective therapeutic tool (Fox et al., 2002; Ramig et al., 2004).”
BackgroundAssociation of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease
Simmering, J. E., Welsh, M. J., Liu, L., Narayanan, N. S., & Pottegård, A. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.5157 · Cited by 84
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33
Metadata
- Authors
- Hilker, R.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2005-09-01
- Volume
- 76
- Issue
- 9
- Pages
- 1217-1221
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2128908582
- Cited by
- 173
- References
- 2
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.